| P50 | author | Peter L Choyke | Q90059714 |
| P2093 | author name string | Jacek Capala | |
| | Kirsten Bouchelouche | |
| P2860 | cites work | Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression | Q24654019 |
| | Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer | Q28236013 |
| | Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer | Q28254156 |
| | Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer | Q33361082 |
| | Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody | Q33504321 |
| | In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. | Q33649303 |
| | 'Image and treat': an individualized approach to urological tumors | Q33792596 |
| | A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? | Q34408322 |
| | Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer | Q35645376 |
| | Antibody-based therapeutics: focus on prostate cancer | Q36366526 |
| | Imaging techniques for prostate cancer: implications for focal therapy | Q36460818 |
| | Clinical utility of radiolabeled monoclonal antibodies in prostate cancer | Q36490589 |
| | Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. | Q36619673 |
| | Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review | Q36998779 |
| | Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen | Q37183709 |
| | Novel tracers and their development for the imaging of metastatic prostate cancer | Q37321810 |
| | Targeted therapies for prostate cancer against the prostate specific membrane antigen | Q37387347 |
| | Emerging therapies in castrate-resistant prostate cancer | Q37442526 |
| | Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer | Q37457888 |
| | Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. | Q39770729 |
| | Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer | Q39808317 |
| | A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. | Q40246099 |
| | Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line | Q41123022 |
| | Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids | Q41297571 |
| | N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer | Q41913170 |
| | Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy | Q42140893 |
| | Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer | Q43193122 |
| | PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. | Q51766972 |
| | Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. | Q53584696 |
| | A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine | Q73645200 |
| | Prostate cancer | Q81295804 |
| | Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer | Q81662607 |
| P433 | issue | 44 | |
| P304 | page(s) | 55-61 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Discovery Medicine | Q5281940 |
| P1476 | title | Prostate specific membrane antigen- a target for imaging and therapy with radionuclides | |
| P478 | volume | 9 | |